VEGFA and breast cancer: While targeting of HIF1 may tackle with breast cancer and diabetes associated worse prognosis, the application of combination therapy such as the addition of VEGF expression enhancers may prevent the implications of diabetic complications that may accompany the therapeutic down-regulation of HIF1 in patients with both T2DM and breast cancer.